Table 1 Characteristics of study participants in different chronic kidney disease stages at study entry (N = 119.871).
CKD stages | Stage 1, high | Stage 1 | Stage 2 | Stage 3 |
---|---|---|---|---|
eGFR, ml/min/1.73 m2 | >105 | 90–105 | 60–89 | 30–59 |
Number | 28,013 | 40,502 | 45,665 | 5,691 |
Male (%) | 18.54 | 31.57 | 47.31 | 55.82 |
Age < 50 (%) | 93.69 | 44.52 | 30.93 | 3.67 |
BMI (%) | ||||
   Underweight | 4.91 | 2.37 | 1.99 | 2.42 |
   Normal | 66.78 | 58.94 | 53.41 | 46.34 |
   Overweight or obese | 28.31 | 38.69 | 44.59 | 51.24 |
Current cigarette smoker (%) | 12.27 | 14.07 | 17.08 | 16.53 |
Non-abstainer (%) | 38.47 | 37.89 | 38.16 | 25.27 |
Education level (%) | ||||
Illiterate/did not attend school | 1.44 | 7.67 | 14.11 | 30.84 |
Elementary school | 10.06 | 28.05 | 29.66 | 36.27 |
Junior high and school | 58.42 | 44.75 | 38.67 | 24.54 |
College and graduate school | 30.09 | 19.53 | 17.55 | 8.34 |
Comorbidities, % | ||||
Diabetes | 4.43 | 8.62 | 9.79 | 21.52 |
Hypertension | 5.10 | 14.84 | 24.37 | 55.65 |
Ischemic heart disease | 1.27 | 4.31 | 8.10 | 20.31 |
Myocardial infarction | 0.05 | 0.11 | 0.31 | 1.04 |
Cardiac dysrhythmia/atrial fibrillation | 1.28 | 2.09 | 3.39 | 7.68 |
Congestive heart failure | 0.29 | 0.85 | 1.61 | 5.89 |
Stroke | 0.23 | 0.77 | 1.60 | 5.31 |
Peripheral vascular disease | 0.11 | 0.42 | 0.53 | 1.05 |
Disorders of lipid metabolism | 4.60 | 11.35 | 14.30 | 25.65 |
Chronic lung disease | 4.32 | 6.31 | 9.54 | 17.71 |
Chronic liver disease | 5.53 | 7.03 | 7.89 | 8.65 |
Autoimmune disease | 2.30 | 2.68 | 2.82 | 3.46 |
Dementia | * | 0.05 | 0.32 | 1.56 |
Cancer | 0.95 | 1.68 | 2.32 | 4.41 |
Charlson comorbidity score, mean (SD) | 0.22 (0.60) | 0.37 (0.80) | 0.50 (0.92) | 1.08 (1.39) |
Laboratory data | ||||
Albumin in g/dL, mean (SD) | 4.62 (0.26) | 4.61 (0.25) | 4.60 (0.26) | 4.51 (0.30) |
Dipstick proteinuria (%)** | ||||
− | 91.74 | 90.48 | 87.26 | 72.66 |
+/− | 7.02 | 8.05 | 10.26 | 16.64 |
1+ | 0.89 | 1.03 | 1.75 | 6.36 |
≥2+ | 0.34 | 0.43 | 0.73 | 4.34 |
Drug use and hospitalization history, % | ||||
Systemic steroid use >30 days before study entry | 0.69 | 1.07 | 1.55 | 3.27 |
Hospitalization within 6 months before enrollment | 2.47 | 2.41 | 2.94 | 6.47 |
Hospitalization within 6 months before index hospitalization for infection | 0.87 | 1.60 | 3.12 | 9.58 |